Lead program VMT-α-NET in neuroendocrine tumors continues to demonstrate a favorable tolerability profile with durable disease control and deepening of tumor response with longer follow-up, as ...
LTR Pharma recently announced the dosing of the first patients in the Phase II study of SPONTAN ®, which is evaluating the safety, tolerability and pharmacokinetic profile of LTR Pharma’s rapid acting ...
Vista Gold Corp. (AMEX:VGZ) Q4 2025 Earnings Call Transcript March 13, 2026 Operator: Good day, ladies and gentlemen, and ...
Howard Hughes's chaotic estate settlement after his death without a will highlights a growing issue: most people today have ...
Silence Therapeutics plc, Nasdaq: SLN, a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today reported financial results for the fourth quarter and full year ...
FDA's elevated meeting status signals transition from biomarker data discussions to Accelerated Approval discussions OS ...
Advanced Global Phase 3 Program for Treatment of Hepatitis C Virus (HCV) in 2025 with Topline Results from North American C-BEYOND Trial Expected Mid-2026 and Topline Results from C-FORWARD Trial Outs ...
RAP-219's lead program demonstrated robust and consistent activity in patients with focal onset seizures (FOS) in Phase 2a trial; initiation of Phase 3 program expected in the second quarter of 2026RA ...
The Cavorite X7's Low Projected Operating Cost Has Been Verified by a Leading Independent Audit Firm TORONTO, ON / ...
The U.S. International Trade Commission’s ruling favoring GoPro against Insta360 strengthened intellectual property protections and was cited as validation of GoPro's innovation-centric business model ...
If any pages are missing or are from a different edition, USCIS may reject your form, the agency has warned.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results